Extended-spectrum β-lactamases in North America, 1987-2006

131Citations
Citations of this article
141Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Extended-spectrum β-lactamases (ESBLs) derived from the TEM-1 β-lactamase were first identified in the USA in outbreak strains of Klebsiella pneumoniae in the middle to late 1980s, together with the SHV-5 ESBL. The TEM-10, TEM-12 and TEM-26 enzymes have remained in US hospitals, but have been joined by other ESBLs that are variants of the SHV-1 broad-spectrum β-lactamase. In the most recent surveys from hospitals in the eastern part of the USA, the most prominent ESBLs have been the SHV-7 and SHV-12 enzymes. In Canada, a wider variety of ESBLs has been identified, with multiple members of the TEM, SHV and CTX-M classes being represented in surveillance isolates. SHV-type and CTX-M ESBLs have appeared in many Canadian isolates, with an outbreak of CTX-M-14-related enzymes from Calgary, but limited TEM-derived ESBLs. Surprisingly, few CTX-M ESBLs have yet been reported in the USA, in contrast to the rest of the world, where the CTX-M enzymes have become a predominant ESBL family. © 2008 The Author Journal Compilation © 2008 European Society of Clinical Microbiology and Infectious Diseases.

Author supplied keywords

Cite

CITATION STYLE

APA

Bush, K. (2008). Extended-spectrum β-lactamases in North America, 1987-2006. Clinical Microbiology and Infection. Blackwell Publishing Ltd. https://doi.org/10.1111/j.1469-0691.2007.01848.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free